Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasuaki Sagara

Showing results (111-120 of 132) with videos related to

Pageof 14
Sort By:
Breast Cancer (Tokyo, Japan)|October 9, 2023
Long-term prognostic value of the GenesWell BCT score in Asian women with hormone receptor-positive/HER2-negative early breast cancerYoshitaka Fujiki, Masahiro Kashiwaba, Mutsumi Sato, et al.
Trials|June 10, 2020
Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)Toshinari Yamashita, Norikazu Masuda, Shigehira Saji, et al.
Breast Cancer (Tokyo, Japan)|June 10, 2026
Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancerTsuguo Iwatani, Norikazu Masuda, Shigehira Saji, et al.
Breast Cancer Research and Treatment|July 8, 2026
Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALDNorikazu Masuda, Shigehira Saji, Yasuyuki Kojima, et al.
Breast Cancer Research and Treatment|September 9, 2023
Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancerShinsuke Sasada, Naoto Kondo, Hiroya Hashimoto, et al.
Japanese Journal of Clinical Oncology|January 30, 2026
A randomized controlled trial of metastasis-directed therapy for oligometastases in breast cancer: OLIGAMI trial (JCOG2110)Keita Sasaki, Toshiyuki Ishiba, Ikuno Nishibuchi, et al.
The British Journal of Surgery|May 16, 2026
Primary tumour resection reduces the risk of major local morbidity in de novo stage IV breast cancer: secondary data analysis from the JCOG1017 randomized controlled trialMakoto Ishitobi, Kiyo Tanaka, Akihiko Shimomura, et al.
Breast Cancer Research and Treatment|August 21, 2020
Breast cancer survival among Japanese individuals and US residents of Japanese and other origins: a comparative registry-based studyRin Ogiya, Naoki Niikura, Hiraku Kumamaru, et al.
Breast Cancer (Tokyo, Japan)|April 16, 2026
Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017Kiyo Tanaka, Akihiko Shimomura, Makoto Ishitobi, et al.
Breast Cancer : Basic and Clinical Research|July 18, 2018
Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational StudyHiroyasu Yamashiro, Masataka Sawaki, Norikazu Masuda, et al.
Pageof 14

Showing results (111-120 of 132) with videos related to

Sort By:
Pageof 14
Breast Cancer (Tokyo, Japan)|October 9, 2023
Long-term prognostic value of the GenesWell BCT score in Asian women with hormone receptor-positive/HER2-negative early breast cancerYoshitaka Fujiki, Masahiro Kashiwaba, Mutsumi Sato, et al.
Trials|June 10, 2020
Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)Toshinari Yamashita, Norikazu Masuda, Shigehira Saji, et al.
Breast Cancer (Tokyo, Japan)|June 10, 2026
Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancerTsuguo Iwatani, Norikazu Masuda, Shigehira Saji, et al.
Breast Cancer Research and Treatment|July 8, 2026
Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALDNorikazu Masuda, Shigehira Saji, Yasuyuki Kojima, et al.
Breast Cancer Research and Treatment|September 9, 2023
Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancerShinsuke Sasada, Naoto Kondo, Hiroya Hashimoto, et al.
Japanese Journal of Clinical Oncology|January 30, 2026
A randomized controlled trial of metastasis-directed therapy for oligometastases in breast cancer: OLIGAMI trial (JCOG2110)Keita Sasaki, Toshiyuki Ishiba, Ikuno Nishibuchi, et al.
The British Journal of Surgery|May 16, 2026
Primary tumour resection reduces the risk of major local morbidity in de novo stage IV breast cancer: secondary data analysis from the JCOG1017 randomized controlled trialMakoto Ishitobi, Kiyo Tanaka, Akihiko Shimomura, et al.
Breast Cancer Research and Treatment|August 21, 2020
Breast cancer survival among Japanese individuals and US residents of Japanese and other origins: a comparative registry-based studyRin Ogiya, Naoki Niikura, Hiraku Kumamaru, et al.
Breast Cancer (Tokyo, Japan)|April 16, 2026
Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017Kiyo Tanaka, Akihiko Shimomura, Makoto Ishitobi, et al.
Breast Cancer : Basic and Clinical Research|July 18, 2018
Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational StudyHiroyasu Yamashiro, Masataka Sawaki, Norikazu Masuda, et al.
Pageof 14